Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05191381 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Immune Modulation by Exosomes in COVID-19

Study acronym: IMECOV19
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 17, 2024 (before its estimated July 31, 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Jul 31, 2022 to Jul 31, 2025
    • Study completion date: Dec 31, 2022 to Dec 31, 2026
    v3
  2. Secondary endpoints revised (2)
    • Study site revised
    • Publications: 15 to 17
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Following whole blood stimulation with mesenchymal stem cell derived exosomes, immune phenotype, cytokine release and mRNA expression patterns from critically ill patients with COVID-19 will be determined.
Trial Details
NCT Number NCT05191381
Lead Sponsor University of Ulm
Conditions
(from sponsor)		 COVID-19, Critical Illness, Hypercytokinemia, Lung Fibrosis
Related terms COVID-19, Critical Illness, Cytokine Release Syndrome, Pulmonary Fibrosis, Sepsis
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov